Dabrafenib and Trametinib for Cancer: Uses & Side Effects

Dabrafenib and trametinib are two targeted cancer drugs taken together as a pill-based combination therapy. They work by blocking two linked proteins in a cell-growth signaling chain that, when mutated, drives several types of cancer. The combination is approved for melanoma, certain lung cancers, anaplastic thyroid cancer, and, since 2022, any solid tumor carrying a specific mutation called BRAF V600E. The pairing is effective, but it comes with a distinctive side-effect profile, most famously fevers that affect at least half of patients.

How the Combination Works

Both drugs target different steps in the same signaling pathway that tells cells to grow and divide. The BRAF V600E mutation creates a version of the BRAF protein that is stuck in the “on” position, sending continuous growth signals to the cell regardless of whether the body is actually telling it to grow. This sustained activation promotes unchecked cell proliferation, survival, and blood-vessel formation around tumors.¹ Dabrafenib blocks the mutant BRAF protein directly. Trametinib blocks MEK, the next protein downstream. By hitting two points in the same chain, the combination makes it harder for cancer cells to find a workaround and keep growing.

This dual-blockade strategy consistently outperforms dabrafenib or other BRAF inhibitors used alone. A meta-analysis of published trials found that the combination improved response rates, roughly doubled the time before tumors progressed, and reduced the risk of death by about 30% compared with a single BRAF inhibitor.² The skin-related side effects that plague BRAF inhibitors used alone, such as secondary skin cancers, also tend to be less common with the combination, though gastrointestinal symptoms and fevers increase.

Melanoma, the Primary Use

Melanoma is where dabrafenib plus trametinib was first proven and remains most widely used. Roughly 40 to 50 percent of melanomas carry a BRAF V600 mutation, making a large share of patients eligible. In the COMBI-v trial, the combination produced a one-year survival rate of about 72%, compared with 65% for vemurafenib (another BRAF inhibitor) alone, and the median time before cancer progressed was 11.4 months versus 7.3 months.³

Longer follow-up from pooled data of over 560 patients painted a clearer picture of durable benefit. About a third of patients treated with the combination were alive at five years, and roughly one in five had not yet had their cancer progress. Patients who achieved a complete response fared best: their five-year survival rate reached about 71%.⁴ Three-year outcomes were also strongly influenced by tumor burden. Patients with normal lactate dehydrogenase levels and fewer than three metastatic sites had a three-year survival rate of about 62%, whereas those with elevated LDH and more widespread disease were closer to 25%.⁵

After Surgery for Earlier-Stage Melanoma

The combination also has a role after surgery for stage III melanoma, where the goal is to prevent recurrence rather than shrink an existing tumor. In the COMBI-AD trial, one year of dabrafenib plus trametinib after surgical removal of stage III melanoma cut the risk of relapse roughly in half compared with placebo, with a three-year relapse-free survival rate of 58% versus 39%.⁶ After nearly ten years of follow-up, the benefit in relapse-free survival persisted, and the risk of death was about 20% lower. Among patients specifically carrying the V600E mutation, the mortality reduction was closer to 25%, though the overall survival difference did not cross the threshold for statistical significance.⁷

Immunotherapy First, or Targeted Therapy First?

For patients with BRAF-mutant metastatic melanoma, a pressing real-world question is which treatment to start with: dabrafenib plus trametinib, or combination immunotherapy with nivolumab and ipilimumab? The DREAMseq trial directly tested the sequencing question. Patients who started with immunotherapy (nivolumab plus ipilimumab) and switched to dabrafenib plus trametinib at progression had a two-year survival rate of about 72%, compared with roughly 52% for those who started with the targeted therapy and then switched to immunotherapy.⁸

The trial’s conclusion was straightforward: for most patients, immunotherapy first and targeted therapy second is the better sequence. That said, dabrafenib and trametinib work faster and more predictably. When a patient’s tumor burden is high and symptoms are severe, oncologists sometimes lead with targeted therapy to shrink the cancer quickly and then consider switching to immunotherapy. The targeted drugs also remain the mainstay for patients who cannot tolerate immunotherapy or whose tumors progress on it.

Non-Small Cell Lung Cancer

BRAF V600E mutations are rare in lung cancer, turning up in only about 1 to 2 percent of non-small cell lung cancer (NSCLC) cases. But for those patients, dabrafenib plus trametinib delivers meaningful tumor shrinkage. In a phase 2 trial, about 64% of previously untreated patients saw their tumors shrink substantially.⁹ Patients who had already received prior chemotherapy saw similar response rates, around 63%.¹⁰

Updated long-term data showed median overall survival in the range of 17 to 18 months, with roughly one in five patients still alive at five years.¹¹ Those numbers are encouraging for a disease historically difficult to treat with targeted agents, though they reflect a smaller, single-arm trial without a direct comparator.

Anaplastic Thyroid Cancer

Anaplastic thyroid cancer is one of the most aggressive cancers in humans, often fatal within months. For the subset carrying a BRAF V600E mutation, dabrafenib plus trametinib has been a genuine breakthrough. In the ROAR basket study, about 56% of patients responded, and the median overall survival was roughly 14.5 months, with about half of patients alive at one year.¹² An earlier interim analysis of the same study reported an even higher response rate of 69% among the initial 16 patients, with 12-month survival of 80%.¹³ For a cancer type where older chemotherapies barely moved the needle, these results represent a real change in the outlook for eligible patients.

Tumor-Agnostic Approval and Other Cancers

In 2022, the FDA granted dabrafenib plus trametinib a tissue-agnostic approval, meaning it can be used for any solid tumor carrying a BRAF V600E mutation as long as no satisfactory alternative treatment exists. This was based on data from basket trials showing responses across a range of cancers including biliary tract cancer, low-grade and high-grade gliomas, hairy cell leukemia, and others.¹⁴

The response rates in the broader basket setting are generally more modest than in melanoma or thyroid cancer. A Japanese multicenter basket trial across various tumor types reported an overall response rate of 28%, though the disease control rate was 84%, suggesting the drugs stabilize many tumors even when they do not produce dramatic shrinkage.¹⁵ The tissue-agnostic label is a lifeline for patients with rare BRAF-mutant cancers that would never have enough patients for a dedicated trial.

Use in Children

Pediatric low-grade gliomas, the most common brain tumors in children, carry BRAF V600 mutations in a meaningful minority of cases. A randomized trial published in 2023 found that dabrafenib plus trametinib produced an objective response in 47% of children, compared with 11% on standard chemotherapy, and the median time before cancer progressed was 20.1 months versus 7.4 months.¹⁶ Age-based and weight-based dosing of the combination achieved target drug levels with a manageable safety profile in younger patients.¹⁷

For families, a major practical advantage is that both drugs come in oral form, including liquid formulations for young children. This avoids intravenous chemotherapy infusions, a meaningful quality-of-life difference for pediatric patients who may need months of treatment.

Fevers and Other Common Side Effects

The most distinctive side effect of dabrafenib plus trametinib is fever, medically called pyrexia. It affects at least half of treated patients and can be more than a mild annoyance.¹⁸ Without prompt management, fevers can escalate into a syndrome involving chills, low blood pressure from dehydration, and, in rare cases, organ complications. Standard practice now is to interrupt both drugs at the first sign of fever (a temperature of 38°C or 100.4°F) and restart at the same dose once the patient has been symptom-free for at least 24 hours.¹⁹ Fevers tend to occur in waves, most commonly in the first few months, and many patients eventually develop a pattern their medical team can anticipate and manage proactively.

Beyond fevers, the commonly reported side effects include:

Fatigue: persistent tiredness that can affect daily life throughout treatment.
Rash: skin reactions are common with trametinib in particular, though the combination tends to cause fewer of the severe skin cancers (like squamous cell carcinoma) that solo BRAF inhibitors sometimes trigger.²⁰
Diarrhea: more frequent with the combination than with a BRAF inhibitor alone, and sometimes accompanied by nausea.
Joint and muscle pain: in rare cases, trametinib has been linked to severe muscle rigidity and pain, particularly in younger patients.²¹

Serious Adverse Events

The most concerning serious side effect involves the heart. Trametinib can reduce the heart’s pumping ability, measured as a drop in left ventricular ejection fraction. A meta-analysis found that the combination carried roughly a threefold higher risk of ejection fraction decreases compared with a BRAF inhibitor alone, affecting about 8% of patients versus 2% in the control group.²² Hypertension is also more common, occurring in roughly one in five patients on the combination. In a longitudinal study, about 27% of patients developed some degree of cardiac dysfunction, though no one in that cohort progressed to severe heart failure or symptomatic disease.²³ Patients typically undergo echocardiograms or similar heart imaging before starting treatment and periodically during therapy.

Eye problems, while uncommon, can be serious. Trametinib is associated with central serous retinopathy and macular edema, a buildup of fluid in the part of the retina responsible for sharp vision. In one case report, a patient’s visual acuity dropped to only being able to count fingers, but recovered substantially after the drugs were stopped and steroid treatment was given.²⁴ Patients are usually advised to report any new blurring or visual disturbance promptly.

Lung inflammation (pneumonitis) is rare but has been reported, with an incidence of about 2.4% in one melanoma dataset. In rare instances, it can be rapidly fatal, particularly in lung cancer patients whose underlying disease may be confused with the drug side effect.²⁵

Why Tumors Eventually Stop Responding

Most patients who initially respond to dabrafenib plus trametinib will eventually see their cancer start growing again. Understanding why helps explain the ongoing search for better combinations. In one study of tumors that progressed on the combination, 82% had developed a new genetic change that reactivated the same growth signaling pathway the drugs were supposed to block. The most common mechanism was extra copies of the BRAF gene itself, found in about a third of resistant tumors, which was a surprising finding since this type of resistance is much less common with solo BRAF inhibitors.²⁶ New mutations in MEK and in another gene called NRAS were also common escape routes.

A broader multi-center analysis confirmed that the resistance landscape is diverse: additional mutations in the signaling pathway, changes in the way receptors on the cell surface are expressed, and activation of alternative survival pathways all contribute. Strikingly, about 42% of resistant samples had no identifiable known resistance driver at all, suggesting there are escape mechanisms researchers have not yet mapped.²⁷ In lung cancer, resistance pathways may differ. One report documented a patient whose cancer acquired a new MET gene alteration after seven months on the combination, opening a completely different signaling bypass.²⁸

Taking the Drugs and Food Interactions

Both dabrafenib and trametinib are taken by mouth. The standard adult dose is dabrafenib 150 mg twice daily and trametinib 2 mg once daily. Current prescribing guidance recommends taking both on an empty stomach, at least one hour before or two hours after a meal. A pharmacokinetic study in healthy volunteers confirmed the rationale: eating even a low-fat, low-calorie meal reduced the amount of drug absorbed by roughly 15 to 25% and delayed the time to peak blood levels. However, the same study noted that an occasional light meal is unlikely to meaningfully alter drug levels once a patient has been on the drugs long enough to reach a steady state.²⁹ In practice, this means a missed fasting window once in a while is not a crisis, but consistently eating with the drugs is worth avoiding.

Tracking Treatment Response With Blood Tests

One emerging approach to monitoring how well dabrafenib plus trametinib is working involves liquid biopsies, blood tests that look for tumor DNA circulating in the bloodstream. In a prospective study of BRAF V600E-mutant lung cancer patients, the mutant DNA was detectable in blood samples for about 62% of patients at baseline. Among those who initially shed detectable tumor DNA, 81% cleared it from their blood within weeks of starting treatment. Clearing the mutation correlated with substantially better outcomes: patients whose blood cleared the mutation had a median progression-free survival of 8.3 months versus just 1.4 months for those who did not. Perhaps most useful clinically, molecular signs of progression showed up in the blood about five weeks before conventional imaging or symptoms detected it.³⁰ This kind of early warning could eventually let oncologists adjust treatment before a patient’s cancer visibly grows, though the approach is not yet part of routine care in most centers.

Quality of Life During Treatment

Cancer treatment effectiveness is only part of the picture. A randomized comparison of dabrafenib plus trametinib versus dabrafenib alone measured patient-reported quality of life throughout treatment. Patients on the combination reported significantly better global health scores at weeks 8, 16, and 24, and their pain scores showed clinically meaningful improvement, on the order of 6 to 13 points on a 100-point scale, at every assessment.³¹ This is a counterintuitive finding, since adding a second drug usually means more side effects. The explanation probably lies in the combination’s better tumor control: if the cancer is shrinking more effectively, cancer-related symptoms like pain diminish, and that improvement outweighs the additional drug-related side effects for many patients.

Cost and Access

Targeted therapies carry high price tags, and dabrafenib plus trametinib is no exception. A cost-effectiveness analysis in Switzerland estimated that, at U.S. market prices, the combination therapy cost an additional roughly 200,000 Swiss francs over vemurafenib monotherapy for a gain of about half a quality-adjusted life-year, landing well above conventional willingness-to-pay thresholds.³² Cost-effectiveness calculations for the pediatric glioma indication in England and Wales were more favorable, falling within the accepted threshold.³³ Generic versions of dabrafenib have begun entering some markets, and trametinib’s patent landscape is evolving, which could substantially change the cost equation in the coming years. For now, access remains uneven globally, with manufacturer patient-assistance programs and national formulary negotiations playing a large role in whether eligible patients can actually get the drugs.